Chardan raised the firm’s price target on Dyne Therapeutics to $50 from $42 and keeps a Buy rating on the shares after the company’s Q2 results and business update. The data presented builds on the company’s January update and increases the firm’s confidence in the company’s FORCE platform to successfully deliver to ex-hepatic targets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
- Dyne Therapeutics price target raised to $43 from $39 at JPMorgan
- Dyne Therapeutics participates in a conference call with JPMorgan
- Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
- Dyne announces new Pompe disease data showing potential of FORCE platform